Cmed Clinical Services Appoints New Chief Medical Officer
Cmed Clinical Services, an innovative, full service CRO providing services to the Biopharma industry worldwide, announced today the appointment of Dr. Bams Abila, MD, PhD, FFPM, to Chief Medical Officer.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151009005298/en/
Dr. Bams Abila, Chief Medical Officer, Cmed Clinical Services (Photo: Business Wire)
In this role, Dr. Abila will be responsible for leading the development and operation of Cmed’s medical function, providing leadership and strategic guidance on medical and scientific matters. He will also provide general support and training to the medical and consulting groups across Cmed to ensure the safe, legal, ethical and optimal drug development design and conduct of clinical studies. He will be based in the UK and brings to Cmed a wealth of experience in the design and delivery of clinical strategies and clinical studies with small molecules and biologicals across several therapy areas in Phases I-III.
“We are delighted to welcome Bams Abila to Cmed” said Dr. David Connelly, Cmed’s CEO. “Bams brings a vast amount of expertise, knowledge and skills in translational medicine, clinical development and drug safety, which will be very valuable not only to Cmed in driving our plans for future growth, but for our clients in maintaining and enhancing the design and conduct of their clinical trials. Bams also has a deep interest in the use of advanced data technologies to enhance the speed and efficiency of drug development which fits very well with the evolution of Cmed’s technology division.”
Dr. Abila has 10 years academic medical research experience and extensive global drug development experience spanning 25 years across several therapeutic areas within pharmaceutical settings, including Aventis, Pfizer, Astellas, AstraZeneca and GSK. He is the Founder and Principal Consultant in Pharmaceutical Medicine of Clintreq Consultancy Ltd, working with both pharmaceutical and biotech companies. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK), Fellow of the Royal Society of Medicine (UK) and is a Member of the British Association of Pharmaceutical Physicians, the British Pharmacological Society and the American Heart Association. He is also a member of the American Society of Clinical Pharmacology and was a founding member of the society’s Biologics Community.
- ends -
Cmed is an innovative full service CRO and a software developer of smart e-clinical data capture and management technologies. Cmed was established in 2000 with the vision to conduct clinical trials better than anyone else, thus saving and helping lives. Cmed has a focus on bringing innovation to the design and conduct of clinical trials, including in the areas of clinical data capture, data management, monitoring. Cmed has two divisions: Cmed Clinical Services and Cmed Technology.
Cmed Clinical Services is a global CRO providing services to the Biopharma industry worldwide. Cmed works with clients to not only deliver the clinical trial services effectively, and with quality, passion, teamwork and superior customer service, but also, especially for full service projects, by understanding the clients commercial and business objectives. Cmed then leverages its in-depth expertise to ensure the development program and/or clinical trial is well designed and conducted as efficiently and as cost effectively as possible. Cmed has particular expertise in the design and conduct of complex, oncology and rare disease trials and the provision of Biometric functional services.
Cmed Technology designed and developed Timaeus: a unique single platform for electronic trial design, paper & electronic data capture, monitoring, coding, data management and reporting. Using distributed cloud computing and mobile technologies, Timaeus has been deployed in over 400 clinical trials and has successfully passed multiple audits. The unique Timaeus design provides a number of benefits to our clients including rapid database build (weeks not months), mid-trial updates without down-time and non-reliance on the internet. These benefits lead to many advantages including the removal of EDC build from study start-up, no restriction on investigator site selection, no negative impact on recruitment timelines due to design changes, and elevated investigator motivation.
Anna Forster, Marketing Manager
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom